Drugs such as sorafenib, a multikinase inhibitor used for HCC-treatment, decrease p65 expression and its activity, resulting in downregulation of molecular intermediaries for the promotion, proliferation, and expression of cell invasion [34]. Here, RELA is linked to hepatocellular carcinoma.